Tokyo Tape
Sign in
← PeptiDream

Quarterly report · Q2

4587.TEDINET S100S6V5
Period2023-01-01 → 2023-06-30
Filed2023-11-09
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed

Amends S100RNSH.

Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥9.4bn2023-01-01 → 2023-06-30Cons.Revenue IFRS
Revenue¥4.5bn2023-04-01 → 2023-06-30dCons.Revenue IFRS
Revenue¥26.9bn2022-01-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥5.0bn2022-01-01 → 2022-06-30Cons.Revenue IFRS
Revenue¥4.6bn2022-04-01 → 2022-06-30dCons.Revenue IFRS
Operating income−¥986m2023-01-01 → 2023-06-30Cons.Operating profit loss IFRS
Operating income−¥720m2023-04-01 → 2023-06-30dCons.Operating profit loss IFRS
Operating income−¥1.7bn2022-01-01 → 2022-06-30Cons.Operating profit loss IFRS
Operating income−¥499m2022-04-01 → 2022-06-30dCons.Operating profit loss IFRS
Profit before tax−¥1.1bn2023-01-01 → 2023-06-30Cons.Profit loss before tax IFRS
Profit before tax−¥711m2023-04-01 → 2023-06-30dCons.Profit loss before tax IFRS
Profit before tax¥6.7bn2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥1.6bn2022-01-01 → 2022-06-30Cons.Profit loss before tax IFRS
Profit before tax−¥467m2022-04-01 → 2022-06-30dCons.Profit loss before tax IFRS
Net income (owners)−¥729m2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥480m2023-04-01 → 2023-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥7.6bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥1.1bn2022-01-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥303m2022-04-01 → 2022-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥729m2023-01-01 → 2023-06-30Cons.Profit loss IFRS
Net income−¥480m2023-04-01 → 2023-06-30dCons.Profit loss IFRS
Net income¥7.6bn2022-01-01 → 2022-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥1.1bn2022-01-01 → 2022-06-30Cons.Profit loss IFRS
Net income−¥303m2022-04-01 → 2022-06-30dCons.Profit loss IFRS
Total assets¥57.7bnat 2023-06-30Cons.Assets IFRS
Total assets¥63.9bnat 2022-12-31Cons.Assets IFRS
Total assets¥52.4bnat 2022-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥26.7bnat 2023-06-30Cons.Liabilities IFRS
Total liabilities¥31.8bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥31.0bnat 2023-06-30Cons.Equity IFRS
Net assets / equity¥32.0bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥24.7bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥25.4bnat 2021-12-31dCons.Equity IFRS
Equity (owners)¥31.0bnat 2023-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥32.0bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥24.7bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥11.2bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥5.2bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥6.4bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.7bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥8.8bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow−¥83m2022-01-01 → 2022-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥493m2022-01-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥798m2023-01-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥27.4bn2022-01-01 → 2022-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥26.7bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥2.3bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥20.8bn2022-01-01 → 2022-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥21.6bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-5.622023-01-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-3.72023-04-01 → 2023-06-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥58.192022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-8.722022-01-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-2.332022-04-01 → 2022-06-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥-5.622023-01-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-3.72023-04-01 → 2023-06-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥58.142022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-8.722022-01-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-2.332022-04-01 → 2022-06-30dCons.Diluted earnings loss per share IFRS
Equity ratio53.8%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio50.2%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio47.0%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 22
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-06-30−¥30m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-06-30−¥30m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥1.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥1.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2023-01-01 → 2023-06-30−¥1.2bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥8.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥8.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥30m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-06-30¥228m
—segment totalrevenue2023-01-01 → 2023-06-30¥9.5bn
—segment totalrevenue external2023-01-01 → 2023-06-30¥9.4bn
—segment totalrevenue intersegment2023-01-01 → 2023-06-30¥30m
—segment totalsegment profit2023-01-01 → 2023-06-30−¥941m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥1.1bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥1.1bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2022-01-01 → 2022-06-30−¥1.4bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥3.9bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥3.9bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-06-30¥114m
—segment totalrevenue2022-01-01 → 2022-06-30¥5.0bn
—segment totalrevenue external2022-01-01 → 2022-06-30¥5.0bn
—segment totalsegment profit2022-01-01 → 2022-06-30−¥1.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 634
ItemContextValueUnit
Borrowings ncl IFRSPrior1YearInstant18357797000JPY
Borrowings ncl IFRSCurrentQuarterInstant17260359000JPY
Other financial liabilities ncl IFRSPrior1YearInstant2327082000JPY
Other financial liabilities ncl IFRSCurrentQuarterInstant2294335000JPY
Retirement benefit liability ncl IFRSPrior1YearInstant108450000JPY
Retirement benefit liability ncl IFRSCurrentQuarterInstant112627000JPY
Non current labilities IFRSPrior1YearInstant20793330000JPY
Non current labilities IFRSCurrentQuarterInstant19667321000JPY
Liabilities IFRSPrior1YearInstant31823734000JPY
Liabilities IFRSCurrentQuarterInstant26683873000JPY
Share capital IFRSPrior1YearInstant3956738000JPY
Share capital IFRSCurrentQuarterInstant3956738000JPY
Capital surplus IFRSPrior1YearInstant4524436000JPY
Capital surplus IFRSCurrentQuarterInstant4498562000JPY
Treasury shares IFRSPrior1YearInstant-607334000JPY
Treasury shares IFRSCurrentQuarterInstant-1085546000JPY
Retained earnings IFRSPrior1YearInstant23848337000JPY
Retained earnings IFRSCurrentQuarterInstant23119323000JPY
Other components of equity IFRSPrior1YearInstant319287000JPY
Other components of equity IFRSCurrentQuarterInstant531546000JPY
Equity attributable to owners of parent IFRSPrior1YearInstant32041465000JPY
Equity attributable to owners of parent IFRSCurrentQuarterInstant31020624000JPY
Equity IFRSPrior1YearInstant32041465000JPY
Equity IFRSCurrentQuarterInstant31020624000JPY
Liabilities and equity IFRSPrior1YearInstant63865200000JPY
Liabilities and equity IFRSCurrentQuarterInstant57704497000JPY
Revenue IFRSPrior1YTDDuration5024397000JPY
Revenue IFRSCurrentYTDDuration9426049000JPY
Cost of sales IFRSPrior1YTDDuration3109783000JPY
Cost of sales IFRSCurrentYTDDuration5464694000JPY
Gross profit IFRSPrior1YTDDuration1914613000JPY
Gross profit IFRSCurrentYTDDuration3961355000JPY
Selling general and administrative expenses IFRSPrior1YTDDuration2413884000JPY
Selling general and administrative expenses IFRSCurrentYTDDuration3429071000JPY
Research and development expenses IFRSPrior1YTDDuration1163717000JPY
Research and development expenses IFRSCurrentYTDDuration1506241000JPY
Other income IFRSPrior1YTDDuration518000JPY
Other income IFRSCurrentYTDDuration3939000JPY
Other expenses IFRSPrior1YTDDuration3227000JPY
Other expenses IFRSCurrentYTDDuration16079000JPY
Operating profit loss IFRSPrior1YTDDuration-1665696000JPY
Operating profit loss IFRSCurrentYTDDuration-986098000JPY
Finance income IFRSPrior1YTDDuration250800000JPY
Finance income IFRSCurrentYTDDuration103153000JPY
Finance costs IFRSPrior1YTDDuration66104000JPY
Finance costs IFRSCurrentYTDDuration124756000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration-109972000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration-103231000JPY
Profit loss before tax IFRSPrior1YTDDuration-1590972000JPY
Profit loss before tax IFRSCurrentYTDDuration-1110932000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-12-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass